Metastatic and recurrent renal cell carcinoma (RCC) – kidney cancer that has spread or returned after initial treatment – requires a tailored approach. While a complete cure is often not possible once the cancer has spread beyond the kidney, effective treatments can control the disease for extended periods and improve quality of life. The primary strategies involve systemic therapies, such as immunotherapy and targeted drugs, with surgery and radiation sometimes used to manage specific symptoms or localized disease.
Understanding Metastatic and Recurrent RCC
When kidney cancer metastasizes, it means cancer cells have broken away from the primary tumor and traveled to distant parts of the body, most commonly the lungs, bones, liver, or brain. Recurrence refers to cancer returning after initial treatment, whether through surgery, radiation, or other means. The key difference is that once the cancer spreads beyond the kidney, surgical removal alone is usually not enough.
The aggressive nature of RCC means that the goal shifts from cure to disease control. However, significant advances in immunotherapy and targeted therapies are allowing patients to live longer, symptom-free lives.
Immunotherapy: Unleashing the Body’s Defenses
Immunotherapy drugs work by boosting the patient’s immune system to recognize and attack cancer cells. This is often the first-line treatment for advanced RCC. A class of drugs called checkpoint inhibitors removes “brakes” on immune cells, allowing them to mount a stronger response against the tumor.
Common immunotherapy medications include:
- Avelumab (Bavencio)
- Interferon
- Interleukin-2 (Proleukin)
- Ipilimumab (Yervoy)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
These drugs are typically administered via IV infusion every 2–6 weeks. While highly effective, immunotherapy can cause side effects like fatigue, nausea, skin rashes, and digestive issues.
Targeted Therapy: Precision Strikes Against Cancer Cells
Targeted therapies block specific proteins that cancer cells need to grow and survive. Unlike chemotherapy, these drugs generally have fewer side effects because they spare healthy cells. They’re often used in combination with immunotherapy, especially when urgent tumor control is needed.
Key targeted therapies for RCC include:
- Axitinib (Inlyta)
- Belzutifan (Welireg)
- Bevacizumab (Avastin)
- Cabozantinib (Cabometyx)
- Everolimus (Afinitor)
- Lenvatinib (Lenvima)
- Pazopanib (Votrient)
- Sorafenib (Nexavar)
- Sunitinib (Sutent)
- Temsirolimus (Torisel)
- Tivozanib (Fotivda)
Most are taken as pills, except for temsirolimus, which is administered intravenously. Side effects may include nausea, fatigue, skin changes, high blood pressure, and heart problems. Biomarker testing is crucial to determine which targeted therapy will be most effective for each patient.
Surgery and Radiation: Localized Control
While not curative in advanced cases, surgery and radiation can play a role in managing metastatic RCC. Nephrectomy (kidney removal) or lymph node dissection may be performed if cancer is confined to the kidney or nearby lymph nodes.
For cancers that have spread to other organs, surgery might be used to remove isolated metastases that cause symptoms. Radiation therapy can shrink tumors causing pain, bleeding, or organ compression. More advanced surgical and radiation techniques include arterial embolization, cryosurgery, and thermal ablation, all designed to destroy cancer cells while minimizing harm to surrounding tissues.
The Path Forward
Treating metastatic and recurrent RCC is complex but increasingly effective. Immunotherapy and targeted therapies have dramatically improved patient outcomes, and ongoing clinical trials continue to explore new options. Patients should discuss all available treatments with their oncologist to create a personalized care plan. Regular monitoring with CT scans is essential to track disease progression and adjust treatment as needed.
Ultimately, while a cure remains elusive in many cases, modern treatments can help patients with advanced RCC live longer, healthier lives.
